UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

Oncoimmunology, 2019-04, Vol.8 (4), p.e1568812

2019

Volltextzugriff (PDF)

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

BMC cancer, 2019-01, Vol.19 (1), p.68-15, Article 68

2019

Volltextzugriff (PDF)

Primary malignant melanoma of the vagina: A case report

Gynecologic oncology reports, 2023-10, Vol.49, p.101266, Article 101266

2023

Volltextzugriff (PDF)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

Scientific reports, 2020-09, Vol.10 (1), p.14607, Article 14607

2020

Volltextzugriff (PDF)

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress

Current oncology (Toronto), 2022-01, Vol.29 (2), p.497-509

2022

Volltextzugriff (PDF)

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Journal for immunotherapy of cancer, 2017-11, Vol.5 (1), p.83-83, Article 83

2017

Volltextzugriff (PDF)

Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology

Seminars in immunology, 2023-05, Vol.67, p.101754-101754, Article 101754

2023

Volltextzugriff (PDF)

A first-in-human, open-label, phase I trial of daily oral zelenirstat, an NMT inhibitor, in patients with relapsed/refractory advanced cancer including gastrointestinal cancers

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.129-129

2024

Volltextzugriff (PDF)

Final results of a first-in-human phase I dose escalation trial of daily oral zelenirstat, a n-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3082-3082

2024

Volltextzugriff (PDF)

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

The lancet oncology, 2021-05, Vol.22 (5), p.643-654

2021

Volltextzugriff (PDF)

A First-in-Human, Open-Label, Phase I Dose Escalation Trial of Daily Oral Nmt Inhibitor Zelenirstat in Patients with Relapsed/Refractory B-Cell Lymphomas and Advanced Solid Tumors

Blood, 2023-11, Vol.142 (Supplement 1), p.6241-6241

2023

Volltextzugriff (PDF)

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Journal of clinical oncology, 2023-01, Vol.41 (1), p.75-85

2023

Volltextzugriff (PDF)

A First in Class, Open-Label, First-in-Human, Phase I Trial of Daily Oral Pclx-001

Blood, 2022-11, Vol.140 (Supplement 1), p.12057-12058

2022

Volltextzugriff (PDF)

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet respiratory medicine, 2021-05, Vol.9 (5), p.522-532

2021

Volltextzugriff (PDF)

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)

Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2), p.P259-P259, Article P259

2015

Volltextzugriff (PDF)

A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15094-e15094

2023

Volltextzugriff (PDF)

Uveal melanoma: Real-world analysis of immune checkpoint inhibitors efficacy and lymphocyte-to-monocyte ratio as a biomarker of response

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21590-e21590

2022

Volltextzugriff (PDF)

Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9561-9561

2019

Volltextzugriff (PDF)

Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6050-6050

2023

Volltextzugriff (PDF)

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

The lancet oncology, 2021-05, Vol.22 (5), p.655-664

2021

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Aktive Filter

KollektionNature_系列刊

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(74)
Berichte
(1)

Sprache

Englisch
(75)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Primary malignant melanoma of the vagina: A case report

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology

A first-in-human, open-label, phase I trial of daily oral zelenirstat, an NMT inhibitor, in patients with relapsed/refractory advanced cancer including gastrointestinal cancers

Final results of a first-in-human phase I dose escalation trial of daily oral zelenirstat, a n-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

A First-in-Human, Open-Label, Phase I Dose Escalation Trial of Daily Oral Nmt Inhibitor Zelenirstat in Patients with Relapsed/Refractory B-Cell Lymphomas and Advanced Solid Tumors

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

A First in Class, Open-Label, First-in-Human, Phase I Trial of Daily Oral Pclx-001

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)

A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

Uveal melanoma: Real-world analysis of immune checkpoint inhibitors efficacy and lymphocyte-to-monocyte ratio as a biomarker of response

Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy

Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Aktive Filter

Suchergebnisse filtern